Orchestra BioMed Holdings, Inc. — Form 8-K
Filed November 9, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 76/100
What the filing says
Orchestra BioMed priced a public offering of 15,000,000 common shares at $5.00 per share (gross proceeds: $75M), with underwriters Piper Sandler and TD Securities granted a 30-day option to purchase up to 2,250,000 additional shares at the same price. Net proceeds will fund AVIM Therapy and BACKBEAT trial, Virtue SAB and Virtue trial, and general corporate purposes. Offering expected to close November 9, 2026.
Why this rating
Dilutive equity raise of ~$75M gross (26% of $63.4M market cap) meaningfully dilutes shareholders; typical for small-cap biotech but material to capital structure and near-term stock price pressure.
Tradability signal
SHORT
conviction 31/100 · expected -0.69% over 4 hrs
SHORT (drift): bad news keeps sliding after dissemination — our one persistent measured edge. Similar past filings (92 in this cell) moved +0.88% in the called direction over 4 hrs; shrunk for sample size that's a +0.69% edge. Price is up 1.8% since the filing hit EDGAR — market hasn't digested it yet. Exit plan: HARD stop 6.1% against entry — 1.4× this stock's measured hourly volatility, fixed, not trailing (trails test terribly on these names) — time exit 4 hrs. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it negative)
before filing · preread $5.70 ▲ 0.00% | at our read · unknown $5.70 | +10 min · unknown $5.86 ▲ 2.81% | +30 min · unknown $5.83 ▲ 2.28% | +1 hr · unknown $5.80 ▲ 1.84% | +4 hrs · unknown $5.75 ▲ 0.96% |
The stock had already moved +0.00% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.